Welcome to the ACR/ARHP Abstracts Website

2018 Late-Breaking Abstracts

• Abstract Number: L01
  New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
• Abstract Number: L02
  Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
• Abstract Number: L03
  Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
• Abstract Number: L04
  Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
• Abstract Number: L05
  Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
• Abstract Number: L06
  Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
• Abstract Number: L07
  VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
• Abstract Number: L08
  High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
• Abstract Number: L09
  Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
• Abstract Number: L10
  Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
• Abstract Number: L11
  Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
• Abstract Number: L12
  Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
• Abstract Number: L13
  Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
• Abstract Number: L14
  Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
• Abstract Number: L15
  The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
• Abstract Number: L16
  Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
• Abstract Number: L17
  Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
• Abstract Number: L18
  A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
• Abstract Number: L19
  Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
• Abstract Number: L20
  Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee